![Joshua S. Salafsky](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Joshua S.
Salafsky was the founder who had held the position of Director & Chief Scientific Officer at BlueLight Therapeutics, Inc. from 2013 to 2018.
BlueLight Therapeutics, Inc. was founded in 2013.
Dr. Salafsky earned a doctorate degree from Stanford University.
Anciens postes connus de Joshua S. Salafsky
Sociétés | Poste | Fin |
---|---|---|
BlueLight Therapeutics, Inc.
![]() BlueLight Therapeutics, Inc. BiotechnologyHealth Technology BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA. | Fondateur | 10/09/2018 |
Formation de Joshua S. Salafsky
Stanford University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
BlueLight Therapeutics, Inc.
![]() BlueLight Therapeutics, Inc. BiotechnologyHealth Technology BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA. | Health Technology |